Gulf International Bank UK Ltd, a well-known institutional investor, has recently sold off 18.6% of their holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the first quarter of this year. According to their latest Form 13F filing with the Securities and Exchange Commission (SEC), Gulf International Bank UK Ltd now only holds 16,261 shares of the biopharmaceutical company’s stocks after selling 3,725 shares.
At the time of its filing, Gulf International Bank UK Ltd’s remaining holdings in Alnylam Pharmaceuticals were valued at $3,257,000. What led them to sell almost one-fifth of their stake is still up for analysis and speculation from industry analysts.
Meanwhile, Alnylam Pharmaceuticals itself had just announced their quarterly earnings results on May 4th prior to GIbUK’s sell-off. The company reported earnings per share (EPS) of ($1.40) for that quarter – more positive than the consensus EPS estimate that predicted ($1.97). This means that Alnylam Pharmaceuticals had beaten expectations by $.57 even though they still had a negative net margin of 93.13% and negative return on equity of 1,287.80%.
However, revenues during that same period amounted to $319.29 million which surpassed analysts’ forecasts by around $6 million dollars – or roughly two percent ($312.53 million). Notably enough, Alnylam Pharmaceuticals’ revenue was also up by nearly fifty percent compared to Q1 2020 even if earnings per share posted negative at ($2.00).
Alnylam Pharmaceuticals is focused mainly on discovering and developing new therapeutics based on ribonucleic acid interference (RNAi). The company has a pipeline filled with RNAi therapeutics designed for different genetic medicines such as cardio-metabolic diseases plus hepatic infectious diseases as well as Central Nervous System (CNS)/ocular diseases.
In light of Gulf International Bank UK Ltd’s recent move and Alnylam Pharmaceuticals’ earnings performance, industry analysts are keeping a keen eye on the company’s activities. This subject has only fueled more financial speculation amongst professionals who continuously try to make sense of the ever-shifting sands of the stock market.
[bs_slider_forecast ticker=”ALNY”]
Alnylam Pharmaceuticals Inc Releases Fourth Quarter Results; Investors Remain Cautiously Optimistic
[stock_market_widget type=”chart” template=”basic” color=”#3946CE” assets=”ALNY” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” api=”yf”]Alnylam Pharmaceuticals Inc, a biopharmaceutical company that is focused on discovering, developing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi), released its fourth-quarter results. The company’s shares opened at $192.69 on Friday with a market cap of $24 billion. The firm has a one-year low of $135.46 and a one-year high of $242.97. Institutional investors have been actively buying and trading the stock, including Belpointe Asset Management LLC who bought new shares during the fourth quarter valued at approximately $25,000 while Northwestern Mutual Wealth Management Co increased their position by 59.4% and now owns 373 shares in the company’s stock valued at $89,000 after acquiring an additional 139 shares in the last quarter.
CI Investments Inc also increased its position in shares of Alnylam Pharmaceuticals by 52.7% during the third quarter with their current ownership of 394 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 136 shares recently and Antipodes Partners Ltd holding new stake in share values worth $28,000 . Moreover, Alnylam Pharmaceuticals has several brokerages keenly observing its performance, including JPMorgan Chase & Co., which dropped their target price for ALNY from $200.00 to $196.00 rating it as ‘neutral’ in March this year while Citigroup lowered their price target from $270 to $265 per share; Canaccord Genuity Group advised to watch out for potential buy-in opportunities within range value such as they have given them level pegging ranking them as ‘buy’. As expected within the pharmaceutical industry opinions differ department wise some calling for caution while others recommended cautious optimism when making informed decisions.
In terms of insider trading activities related news accompanying this corporate earnings report saw several Alnylam Pharmaceuticals employees sell shares of the company. This included President Akshay Vaishnaw selling 2,392 shares of the business’ stock on Thursday 27th April for an average price of $194.59 per share totalling to a transactional cost of $465,459.28, with the president now owning over 17,890 shares in the company. Also CFO Jeffrey V Poulton sold 977 shares at an average price of $194.59 value just over $190k while preserving just under 12k shares in the company. In total insiders sold approximately 17799 shares valued at over $3 million.
Alnylam Pharmaceuticals has a strong pipeline of investigational RNAi therapeutics that focus on genetic medicines, cardio-metabolic diseases alongside hepatic infectious diseases and central nervous system (CNS)/ocular diseases; thus observers remain cautiously optimistic, with seven investment analysts having rated Alnylam as holding so far and fourteen have given them a conclusive ranking of ‘buy’ due to its long term positive outlook with prospects for potent governance regulations keeping stringent control measures updated to maintain robust stability throughout trading times ahead mostly given associated with medical innovations found in relation to RNA interference values technology use. According to data from Bloomberg.com the overall opinion suggests a “moderate buy” rating and consensus price target would be $247.20 per share which is slightly below what it was before recently updates were made dependent on market conditions backed by current observations by experienced analysts who are in charge of keeping investors up-to-date about companies such as Alnylam Pharmaceuticals Inc’ performance trends.
